CA
NZ
UK
AU
IND
US
GE HealthCare Technologies (NASDAQ:GEHC) shares were trading at USD 76.85 on October 28, 2026, up 8.06%, with a relative volume at time of 3.65. The healthcare solutions provider announced an agreement to acquire SOFIE Biosciences on October 5, 2026, and reported third quarter 2026 …
Generate Biomedicines (NASDAQ:GENB) shares were trading at USD 15.00 on October 28, 2026, up 13.55%, with a relative volume at time of 6.52. The clinical-stage company closed its initial public offering on March 2, 2026, and filed its quarterly report on Form 10-Q for …
Inhibrx Biosciences (NASDAQ:INBX) shares were trading at USD 73.00 on October 28, 2026, down 23.69%, with a relative volume at time of 7.90. The clinical-stage biopharmaceutical company reported that the FDA accepted its ozekibart application in June 2026, amended its Oxford loan agreement on …
Labcorp Holdings Inc. (NYSE:LH) shares were trading at USD 363.94 on October 28, 2026, up 9.90%, with a relative volume at time of 3.51. The laboratory services company announced a quarterly dividend on October 21, signed three acquisition agreements after quarter end and reported …
Penumbra (NYSE:PEN) shares were trading at USD 320.08 on October 28, 2026, down 1.22%, with a relative volume at time of 3.01. The thrombectomy company has a pending merger agreement with Boston Scientific Corporation dated January 14, 2026 and filed its Form 10-Q for …
Basic earnings per share growth of 66.40% over one year, a trailing twelve-month P/E of 8.94 and a PEG of -0.08 on an expected basis define ACADIA Pharmaceuticals (NASDAQ:ACAD) as an undervalued growth stock, with shares trading at USD 20.32 on October 28, 2026, …
One-year earnings growth of 1,199.54% in basic earnings per share, paired with a trailing twelve-month P/E ratio of 10.85 and a PEG ratio of -31.81 on an expected basis, puts Aveanna Healthcare (NASDAQ:AVAH) among undervalued growth stocks, with shares trading at USD 13.03 on …
Bristol-Myers Squibb (NYSE:BMY) reported second quarter 2026 net earnings attributable to BMS of $3,317 million, and the undervalued growth stock figures read 82.74% one-year growth in basic earnings per share, a trailing twelve-month P/E of 13.53 and an expected-basis PEG of -16.94, with shares …
Basic earnings per share growth of 227.70% over one year, a trailing twelve-month P/E of 12.46 and a PEG of 0.00 on an expected basis define Indivior (NASDAQ:INDV) as an undervalued growth stock, with shares trading at USD 34.35 on October 28, 2026, down …
● Adjusted diluted earnings were $1.42 per share, while reported earnings fell to 53 cents.
Please wait processing your request...